Compared with the control group, the tumor size and weight of anti-IL-17A and anti-PD-L1 treatment groups were reduced to some extent, the growth rate was significantly slowed down, but the efficacy of the combined treatment was inferior to that of anti-PD-L1 monotherapy (Fig. 6B–D). This evidence concerns the gene IL17A and neoplasm.